Home

COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a pivotal trial that will study the Neovasc Reducer, designed to reduce angina symptoms in patients with refractory angina. The results of this study will complement existing international safety and effectiveness data and support a pre-market approval application (PMA) to the US Food and Drug Administration (“FDA”) for approval of the Reducer device in the USA.

The first patient was enrolled at St Francis Hospital & Heart Center, Roslyn, USA, under the care of Ziad Ali, and principal investigator Evan Shlofmitz. The patient has a history of chronic refractory angina and previously endured multiple cardiac catheterization procedures at various hospitals to treat his recurrent symptoms. None of the previous procedures was successful at alleviating his chest pain.

“Enrolment of the first patient in COSIRA-II is a major step forward for patients in the USA suffering from chronic chest pain,” stated COSIRA-II Executive Steering Committee member Allen Jeremias, St. Francis Hospital & Heart Center, Roslyn, USA. “For the first time, patients that experience the debilitating effects of refractory angina have access to an FDA-designated ‘Breakthrough Medical Device’ in a placebo-controlled trial. The COSIRA-II Trial offers hope for patients that previously had a poor prognosis and faced a future of unrelenting chest pain.”

COSIRA-II is designed to evaluate the safety and effectiveness of the Reducer in treating patients suffering from refractory angina. The randomised, double blinded, placebo-controlled trial will enrol approximately 380 patients in the USA and Canada at as many as 50 investigational sites. The primary endpoint of the trial is the change in exercise tolerance testing time measured at six months via a treadmill test.

“We are pleased to commence COSIRA-II and grateful that the Centers for Medicare and Medicaid Services has determined the device and the procedure are eligible for reimbursement in the USA during the clinical trial,” commented Fred Colen, chief executive officer at Neovasc. “The coverage determination is a big win for us. COSIRA-II is a major investment for the company. We are grateful to our staff and the investigators for their relentless work to finalize all the required deliverables on schedule, such as FDA approval, local hospital review board approval, qualification processes, site training, and all required legal contracts and documentation by the end of 2021, enabling this first enrolment. Finalisation of the reimbursement rate for the trial procedure will enable Medicare beneficiaries eligible for the trial to have greater access.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua google bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua twitter bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua MySpace bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua LinkedIn bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua stumbleupon bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua icio bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua digg bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Chia sẽ qua yahoo bài: First patient enrolled in COSIRA-II trial of Neovasc Reducer

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.